( ARTG ) BELSOMRA is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance.,Following initiation of treatment, continuation should be re-evaluated after 3 months [see Section 5.1 Pharmacodynamic Properties, Clinical trials and Section 4.8 Adverse Effects (Undesirable Effects) for clinical trial durations].

HealthdirectFree Australian health advice you can count on.: TABLET, FILM COATED 5 mg/1

You can help ensure medicines are safe by reporting the side effects you experience. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

•Suvorexant may cause daytime somnolence (excess sleepiness). • Risk of impaired alertness, motor coordination, impaired driving may be seen which increases with increase in the dose. So, patients are advised to take a low dose in case of next-day driving and other activities requiring full mental alertness. • Nighttime sleep-driving and other abnormal behaviors, sleep paraly

OTC

HealthdirectFree Australian health advice you can count on.

5 mg/1, Tablet, film coated

INN: SUVOREXANT

Data updated: 2026-04-18

Available in:

🇬🇧

Form

TABLET, FILM COATED

Dosage

5 mg/1

Route

ORAL

Storage

—

About This Product

Manufacturer

Merck Sharp & Dohme LLC

User Reviews

Reviews reflect personal experiences and are not medical advice. Always consult your doctor.